Search

Your search keyword '"Marazzato, Massimiliano"' showing total 21 results
Start Over Author "Marazzato, Massimiliano" Publication Year Range Last 3 years
21 results on '"Marazzato, Massimiliano"'

1. Role of Gut Microbota in Etiopathogenesis of Chronic Intestinal Psueudo Obstruction

Author

Radocchia, Giulia, primary, Neroni, Bruna, additional, Marazzato, Massimiliano, additional, Capuzzo, Elena, additional, Zuccari, Simone, additional, Pantanella, Fabrizio, additional, Zenzeri, Letizia, additional, Evangelisti, Melania, additional, Vassallo, Francesca, additional, Parisi, Pasquale, additional, Nardo, Giovanni Di, additional, and Schippa, Serena, additional

Published
2024
Full Text
View/download PDF

2. Women Skin Microbiota Modifications during Pregnancy

Author

Radocchia, Giulia, primary, Brunetti, Francesca, additional, Marazzato, Massimiliano, additional, Totino, Valentina, additional, Neroni, Bruna, additional, Bonfiglio, Giulia, additional, Conte, Antonietta Lucia, additional, Pantanella, Fabrizio, additional, Ciolli, Paola, additional, and Schippa, Serena, additional

Published
2024
Full Text
View/download PDF

3. Contributors

Author

Abriouel, Hikmate, primary, Almeida, Milena Evangelista, additional, Barbosa, Joana Cristina, additional, Benomar, Nabil, additional, Bernardes, Andressa Ladeira, additional, Bressan, Josefina, additional, Calatayud, Guillermo Álvarez, additional, Callou, Kátia Rau de Almeida, additional, Campos, Débora A., additional, Cardelle-Cobas, Alejandra, additional, Cassani, Lucía, additional, Castro, Joice da Silva, additional, Cepeda, Alberto, additional, Chaudhary, Nisha, additional, Chaudhary, Vandana, additional, Chieffi, Daniele, additional, Cruz Neto, José Patrocínio Ribeiro, additional, da Costa, Whyara Karoline Almeida, additional, Dangi, Priya, additional, da Silva, Alda Cássia Alves, additional, da Silva, Moisés Tolentino Bento, additional, de Brito Alves, José Luiz, additional, de Moura e Dias, Mariana, additional, de Oliveira, Maria Elieidy Gomes, additional, de Souza, Evandro Leite, additional, de Souza, Eliana Carla Gomes, additional, dos Santos, Carolina Araújo, additional, dos Santos Cruz, Bruna Cristina, additional, De Simone, Claudio, additional, Dejani, Naiara Naiana, additional, Dewan, Aastha, additional, Fanelli, Francesca, additional, Fusco, Vincenzina, additional, Gerbino, Esteban, additional, Gomes, Ana Maria, additional, Gomes, Aline Corado, additional, Gómez-Zavaglia, Andrea, additional, Hassan, Hadeel, additional, Hoffmann, Christian, additional, Joshi, Shourabh, additional, Katia, Sivieri, additional, Lacerda, Diego Cabral, additional, Lamas, Alexandre, additional, Loureiro, Laís Monteiro Rodrigues, additional, Machado, Daniela, additional, Majhenič, Andreja Čanžek, additional, Marazzato, Massimiliano, additional, Marciane, Magnani, additional, Marzet, Christian Boggio, additional, Matijašić, Bojana Bogovič, additional, Melgaço, Ana Clara Correia, additional, Meurman, Jukka, additional, Milagro, Fermin I., additional, Miranda, Jose Manuel, additional, Moreno-Indias, Isabel, additional, Mota, João Felipe, additional, Paulino do Nascimento, Luciana Caroline, additional, Paveljšek, Diana, additional, Peluzio, Maria do Carmo Gouveia, additional, Pereira, Irislene Costa, additional, Pereira, Mariana de Fátima Albuquerque, additional, Pessoa, Wallace Felipe Blohem, additional, Pimentel, Tatiana Colombo, additional, Pintado, Manuela, additional, Ribeiro, Andréia Queiroz, additional, Romano, Carla Cristina, additional, Rosa, Carla de Oliveira Barbosa, additional, Sablania, Vandana, additional, Sampaio, Karoliny Brito, additional, Santos, Thalis Ferreira, additional, Severo, Juliana Soares, additional, Siddqui, Saleem, additional, Sinisterra-Loaiza, Laura I., additional, Stamatova, Iva, additional, Sônia Mariza Luiz, de Oliveira, additional, Tammy Priscilla Chioda, Delfino, additional, Tinahones, Francisco J., additional, Torres-Leal, Francisco Leonardo, additional, Trabazo, Rosaura Leis, additional, Treven, Primož, additional, Trindade da Costa, Paulo César, additional, Voss, Glenise Bierhalz, additional, and Yadav, Ajar Nath, additional

Published
2022
Full Text
View/download PDF

5. Chronic intestinal pseudo-obstruction: associations with gut microbiota and genes expression of intestinal serotonergic pathway

Author

Radocchia, Giulia, primary, Marazzato, Massimiliano, additional, Harbi, Karim Ben, additional, Capuzzo, Elena, additional, Pantanella, Fabrizio, additional, De Giorgio, Roberto, additional, Guarino, Matteo, additional, Costanzini, Anna, additional, Zenzeri, Letizia, additional, Parisi, Pasquale, additional, Ferretti, Alessandro, additional, Felici, Enrico, additional, Palamara, Anna Teresa, additional, Di Nardo, Giovanni, additional, and Schippa, Serena, additional

Published
2024
Full Text
View/download PDF

8. Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial

Author

Corazziari, Enrico Stefano, primary, Gasbarrini, Antonio, additional, D'Alba, Lucia, additional, D'Ovidio, Valeria, additional, Riggio, Oliviero, additional, Passaretti, Sandro, additional, Annibale, Bruno, additional, Cicala, Michele, additional, Repici, Alessandro, additional, Bassotti, Gabrio, additional, Ciacci, Carolina, additional, Di Sabatino, Antonio, additional, Neri, Matteo, additional, Bragazzi, Maria Consiglia, additional, Ribichini, Emanuela, additional, Radocchia, Giulia, additional, Iovino, Paola, additional, Marazzato, Massimiliano, additional, Schippa, Serena, additional, and Badiali, Danilo, additional

Published
2023
Full Text
View/download PDF

9. Poliprotect vs Omeprazole in the relief of heartburn, epigastric pain and burning in patients without erosive esophagitis and gastro-duodenal lesions: A Randomized, Controlled Trial

Author

Corazziari, Enrico Stefano, Gasbarrini, Antonio, D'Alba, Lucia, D'Ovidio, Valeria, Riggio, Oliviero, Passaretti, Sandro, Annibale, Bruno, Cicala, Michele, Repici, Alessandro, Bassotti, Gabrio, Ciacci, Carolina, Di Sabatino, Antonio, Neri, Matteo, Bragazzi, Maria Consiglia, Ribichini, Emanuela, Radocchia, Giulia, Iovino, Paola, Marazzato, Massimiliano, Schippa, Serena, Badiali, Danilo, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Corazziari, Enrico Stefano, Gasbarrini, Antonio, D'Alba, Lucia, D'Ovidio, Valeria, Riggio, Oliviero, Passaretti, Sandro, Annibale, Bruno, Cicala, Michele, Repici, Alessandro, Bassotti, Gabrio, Ciacci, Carolina, Di Sabatino, Antonio, Neri, Matteo, Bragazzi, Maria Consiglia, Ribichini, Emanuela, Radocchia, Giulia, Iovino, Paola, Marazzato, Massimiliano, Schippa, Serena, Badiali, Danilo, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Background: In the treatment of upper GI endoscopy-negative patients with heartburn and epigastric pain or burning, antacids, anti-reflux agents, and mucosal protective agents (MPA) are widely used, alone or as add-on treatment to increase response to proton pump inhibitors, which are not indicated in infancy and pregnancy, and account for significant cost expenditure. Aims methods: In this randomized, controlled, double-blind, double-dummy, multicenter trial assessing the efficacy and safety of MPA Poliprotect (neoBianacid®) versus Omeprazole in the relief of heartburn and epigastric pain/burning, 275 endoscopy-negative outpatients were given a 4-week treatment with Omeprazole (20 mg q.d.) or Poliprotect (5 times a day for the initial 2 weeks, and on-demand thereafter), followed by an open-label 4-week treatment period with Poliprotect on demand. Gut microbiota change was assessed. Results: A 2-week treatment with Poliprotect proved non-inferior to Omeprazole for symptom relief (between-group difference in the change in VAS symptom score: [mean, 95% CI] -5.4, -9.9 to -0.1; -6.2, -10.8 to -1.6; ITT and PP populations, respectively).Poliprotect's benefit remained unaltered after shifting to on-demand intake, with no gut microbiota variation. The initial benefit of Omeprazole was maintained against significantly higher use of rescue medicine sachets (mean, 95% CI: Poliprotect 3.9, 2.8-5.0; Omeprazole 8.2, 4.8-11.6) and associated with an increased abundance of oral cavity genera in the intestinal microbiota. No relevant adverse events were reported in either treatment arm. Conclusions: Poliprotect proved non-inferior to standard-dose Omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastro-duodenal lesions. Gut microbiota was not affected by Poliprotect treatment. The study is registered in Clinicaltrial.gov (NCT03238534) and the EudraCT Database (2015-005216-15).

Published
2023

10. Exploiting Bacteria for Improving Hypoxemia of COVID-19 Patients

Author

Trinchieri, Vito, primary, Marazzato, Massimiliano, additional, Ceccarelli, Giancarlo, additional, Lombardi, Francesca, additional, Piccirilli, Alessandra, additional, Santinelli, Letizia, additional, Maddaloni, Luca, additional, Vassalini, Paolo, additional, Mastroianni, Claudio Maria, additional, and d’Ettorre, Gabriella, additional

Published
2022
Full Text
View/download PDF

11. Gut Microbiota Structure and Metabolites, Before and After Treatment in Early Rheumatoid Arthritis Patients: A Pilot Study

Author

Marazzato, Massimiliano, primary, Iannuccelli, Cristina, additional, Guzzo, Maria Paola, additional, Nencioni, Lucia, additional, Lucchino, Bruno, additional, Radocchia, Giulia, additional, Gioia, Chiara, additional, Bonfiglio, Giulia, additional, Neroni, Bruna, additional, Guerrieri, Francesca, additional, Pantanella, Fabrizio, additional, Garzoli, Stefania, additional, Vomero, Marta, additional, Barbati, Cristiana, additional, Di Franco, Manuela, additional, and Schippa, Serena, additional

Published
2022
Full Text
View/download PDF

13. Genetic Diversity of Antimicrobial Resistance and Key Virulence Features in Two Extensively Drug-Resistant Acinetobacter baumannii Isolates

Author

Marazzato, Massimiliano, primary, Scribano, Daniela, additional, Sarshar, Meysam, additional, Brunetti, Francesca, additional, Fillo, Silvia, additional, Fortunato, Antonella, additional, Lista, Florigio, additional, Palamara, Anna Teresa, additional, Zagaglia, Carlo, additional, and Ambrosi, Cecilia, additional

Published
2022
Full Text
View/download PDF

16. Su1635 PATIENTS WITH NONEROSIVE HEARTBURN AND EPIGATRIC PAIN SYNDROME (EPS) ARE NOT CLINICALLY DISTINGUISHABLE AND BENEFIT OF THE SAME TREATMENT. RCT POST HOC ANALYSIS DATA

Author

Corazziari, Enrico, Gasbarrini, Antonio, D'Alba, Lucia, D'Ovidio, Valeria, Riggio, Oliviero, Passaretti, Sandro, Annibale, Bruno, Cicala, Michele, Repici, Alessandro, Bassotti, Gabrio, Ciacci, Carolina, Sabatino, Antonio Di, Neri, Matteo, Bragazzi, Maria Consiglia, Ribichini, Emanuela, Radocchia, Giulia, Iovino, Paola, Marazzato, Massimiliano, Schippa, Serena, and Badiali, Danilo

Published
2024
Full Text
View/download PDF

17. Mo1318 THE MUCOSAL PROTECTIVE AGENT POLIPROTECT IS AN EFFECTIVE TREATMENT TO MANAGE PPI DE-PRESCRIBING. IN NON-EROSIVE HEARTBURN AND EPIGASTRIC PAIN SYNDROME PATIENTS. RCT POST HOC ANALYSIS DATA

Author

Corazziari, Enrico, Gasbarrini, Antonio, D'Alba, Lucia, D'Ovidio, Valeria, Riggio, Oliviero, Passaretti, Sandro, Annibale, Bruno, Cicala, Michele, Repici, Alessandro, Bassotti, Gabrio, Ciacci, Carolina, Sabatino, Antonio Di, Neri, Matteo, Bragazzi, Maria Consiglia, Ribichini, Emanuela, Radocchia, Giulia, Iovino, Paola, Marazzato, Massimiliano, Schippa, Serena, and Badiali, Danilo

Published
2024
Full Text
View/download PDF

18. Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients

Author

Santinelli, Letizia, primary, Laghi, Luca, additional, Innocenti, Giuseppe Pietro, additional, Pinacchio, Claudia, additional, Vassalini, Paolo, additional, Celani, Luigi, additional, Lazzaro, Alessandro, additional, Borrazzo, Cristian, additional, Marazzato, Massimiliano, additional, Tarsitani, Lorenzo, additional, Koukopoulos, Alexia E., additional, Mastroianni, Claudio M., additional, d'Ettorre, Gabriella, additional, and Ceccarelli, Giancarlo, additional

Published
2022
Full Text
View/download PDF

20. Chronic Intestinal Pseudo-Obstruction: Is There a Connection with Gut Microbiota?

Author

Radocchia, Giulia, primary, Neroni, Bruna, additional, Marazzato, Massimiliano, additional, Capuzzo, Elena, additional, Zuccari, Simone, additional, Pantanella, Fabrizio, additional, Zenzeri, Letizia, additional, Evangelisti, Melania, additional, Vassallo, Francesca, additional, Parisi, Pasquale, additional, Di Nardo, Giovanni, additional, and Schippa, Serena, additional

Published
2021
Full Text
View/download PDF

21. The effect of probiotic administration on metabolomics and glucose metabolism in CF patients

Author

Michal Gur, Nehama Zuckerman‐Levin, Kamal Masarweh, Moneera Hanna, Luca Laghi, Massimiliano Marazzato, Shir Levanon, Fahed Hakim, Ronen Bar–Yoseph, Michael Wilschanski, Lea Bentur, Gur, Michal, Zuckerman-Levin, Nehama, Masarweh, Kamal, Hanna, Moneera, Laghi, Luca, Marazzato, Massimiliano, Levanon, Shir, Hakim, Fahed, Bar-Yoseph, Ronen, Wilschanski, Michael, and Bentur, Lea

Subjects
Pulmonary and Respiratory Medicine, Adult, Blood Glucose, Indoles, Adolescent, Cystic Fibrosis, glucose metabolism, Glutamine, Pilot Projects, Young Adult, Glucose Intolerance, Diabetes Mellitus, Humans, Pilot Project, Mannitol, Cysteine, Prospective Studies, Child, Cytokine, Cystic Fibrosi, Blood Glucose Self-Monitoring, Probiotics, Diabetes Mellitu, Arabinose, Lactulose, CFRD, Dysbiosi, Prospective Studie, Indole, Pediatrics, Perinatology and Child Health, Lactates, Quality of Life, Lactate, Cytokines, Dysbiosis, Insulin Resistance, probiotic, metabolomic, Human
Abstract

Background and objectives Cystic fibrosis (CF)-related diabetes (CFRD) affects 50% of CF adults. Gut microbial imbalance (dysbiosis) aggravates their inflammatory response and contributes to insulin resistance (IR). We hypothesized that probiotics may improve glucose tolerance by correcting dysbiosis. Methods A single-center prospective pilot study assessing the effect of Vivomixx (R) probiotic (450 billion/sachet) on clinical status, spirometry, lung clearance index (LCI), and quality of life (QOL) questionnaires; inflammatory parameters (urine and stool metabolomics, blood cytokines); and glucose metabolism (oral glucose tolerance test [OGTT]), continuous glucose monitoring [CGM], and homeostasis model assessment of IR (HOMA-IR) in CF patients. Results Twenty-three CF patients (six CFRD), mean age 17.7 +/- 8.2 years. After 4 months of probiotic administration, urinary cysteine (p = 0.018), lactulose (p = 0.028), arabinose (p = 0.036), mannitol (p = 0.041), and indole 3-lactate (p = 0.046) significantly increased, while 3-methylhistidine (p = 0.046) and N-acetyl glutamine (p = 0.047) decreased. Stool 2-Hydroxyisobutyrate (p = 0.022) and 3-methyl-2-oxovalerate (p = 0.034) decreased. Principal component analysis, based on urine metabolites, found significant partitions between subjects at the end of treatment compared to baseline (p = 0.004). After 2 months of probiotics, the digestive symptoms domain of Cystic Fibrosis Questionnaire-Revised improved (p = 0.007). In the nondiabetic patients, a slight decrease in HOMA-IR, from 2.28 to 1.86, was observed. There was no significant change in spirometry results, LCI, blood cytokines and CGM. Conclusions Changes in urine and stool metabolic profiles, following the administration of probiotics, may suggest a positive effect on glucose metabolism in CF. Larger long-term studies are needed to confirm our findings. Understanding the interplay between dysbiosis, inflammation, and glucose metabolism may help preventing CFRD.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results